MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer

被引：0
|
作者：
Yan, D. [1 ]
Huelse, J. [1 ]
Parker, R. [1 ]
Wang, X. [2 ,3 ]
Frye, S. [3 ,4 ,5 ]
Earp, H. S. [5 ,6 ]
Deryckere, D. [1 ]
Graham, D. [1 ]
机构：
[1] Childrens Healthcare Atlanta, Aflac Canc & Blood Disorders Ctr, Pediat, Atlanta, GA USA
[2] Ctr Integrat Chem Biol & Drug Discovery, Chem Biol & Med Chem, Chapel Hill, NC USA
[3] Div Chem Biol, Chapel Hill, NC USA
[4] Ctr Integrat Chem Biol & Drug Discovery, Chapel Hill, NC USA
[5] UNC Lineberger Comprehens Canc Ctr, Med, Chapel Hill, NC USA
[6] Sch Med, Pharmacol, Chapel Hill, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 11期
关键词：
Non-small cell lung cancer; EGFR mutation; osimertinib; resistance; MERTK;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.18
引用
下载
收藏
页码：S1147 / S1147
页数：1
相关论文
共 50 条
  • [1] MERTK drives residual tumor growth in EGFR-mutated non-small cell lung cancer cells treated with osimertinib
    Yan, Dan
    Huelse, Justus
    Parker, Rebecca
    Tan, Zikang
    Wang, Xiaodong
    Frye, Stephen, V
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    CANCER RESEARCH, 2020, 80 (16)
  • [2] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Alessandro Leonetti
    Sugandhi Sharma
    Roberta Minari
    Paola Perego
    Elisa Giovannetti
    Marcello Tiseo
    British Journal of Cancer, 2019, 121 : 725 - 737
  • [3] Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
    Leonetti, Alessandro
    Sharma, Sugandhi
    Minari, Roberta
    Perego, Paola
    Giovannetti, Elisa
    Tiseo, Marcello
    BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 725 - 737
  • [4] Safety of osimertinib in EGFR-mutated non-small cell lung cancer
    Mezquita, Laura
    Varga, Andreea
    Planchard, David
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (12) : 1239 - 1248
  • [5] MERTK activation drives osimertinib resistance in EGFR-mutant non small cell lung cancer
    Yan, Dan
    Huelse, Justus M.
    Kireev, Dmitri
    Tan, Zikang
    Chen, Luxiao
    Goyal, Subir
    Wang, Xiaodong
    Frye, Stephen, V
    Behera, Madhusmita
    Schneider, Frank
    Ramalingam, Suresh S.
    Owonikoko, Taofeek
    Earp, H. Shelton
    DeRyckere, Deborah
    Graham, Douglas K.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (15):
  • [6] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Fu, Kai
    Xie, Fachao
    Wang, Fang
    Fu, Liwu
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [7] Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
    Kai Fu
    Fachao Xie
    Fang Wang
    Liwu Fu
    Journal of Hematology & Oncology, 15
  • [8] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [9] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
    Bertoli, Elisa
    De Carlo, Elisa
    Del Conte, Alessandro
    Stanzione, Brigida
    Revelant, Alberto
    Fassetta, Kelly
    Spina, Michele
    Bearz, Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [10] Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
    Zeng, Beilei
    Gan, Kelun
    Yu, Yuanhang
    Hu, Jianping
    Deng, Qiao
    Yin, Chong
    Gao, Xi
    FRONTIERS IN ONCOLOGY, 2024, 14
12345